Walder Wyss advises Ufenau on the acquisition of Dr. Niedermaier Pharma Group

Ufenau Capital Partners has acquired a majority stake in Dr. Niedermaier Pharma Group, a leading producer and supplier of organic nutritional supplements and natural cosmetics with headquarters in Hohenbrunn near Munich (Germany) and in Appenzell.

Founded 1939, Dr. Niedermaier Pharma Group produces and distributes across Europe nutritional supplements, natural cosmetics and beauty liquids in the premium segment based on the patented “Regulatessence”, a highly concentrated, plant-based enzyme digest. This enzyme digest is manufactured in the firm’s own state-of-the-art production facility. With over 50 highly qualified employees, an innovative research team and renowned cooperation partners, Dr. Niedermaier serves a broad and loyal customer base throughout Europe.

Together with Ufenau, the strong market position of Dr. Niedermaier Pharma Group will be expanded through strategic acquisitions, extension of the product portfolio and geographical reach. As part of the transaction, the former shareholders and managers will reinvest in the newly formed group, NZYM, and will continue their successful engagement at Dr. Niedermaier Pharma Group.

Ufenau Capital Partners is a privately owned investment company headquartered in Switzerland that advises private investors, family offices and institutional investors with their investments in private equity. Ufenau is focused exclusively on investments in service companies in German-speaking Europe, Iberia and the Benelux región.

Walder Wyss has advised Ufenau Capital Partners on the transaction. The team was led by partner Stefan Knobloch (corporate/m&a, pictured left) and Fabienne Anner (corporate/m&a, managing associate, pictured right) and further included Letizia Schlegel (corporate/m&a, associate), Christine Leuch (IP/IT, managing associate) and Valentina Eichin (employment,